{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T19:13:32Z","timestamp":1732043612886},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Direct acting antivirals (DAAs) as a curative treatment of hepatitis C have been available for several years and have replaced interferon-containing therapies. However, treatment rates of people who inject drugs (PWID) are declining in Germany, putting the elimination of hepatitis C by 2030 at risk. This study aimed at elucidating the knowledge of, and attitude towards, hepatitis C treatment in a clinical sample of PWID.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Participants were recruited between February 2019 and October 2020 at two opioid agonist therapy (OAT) clinics and two in-patient drug detoxification wards. Based on the European Addiction Severity Index (Europ-ASI), a standardized interview focusing on: sociodemographic data, drug history, risky behavior, infection with hepatitis C virus (HCV) and HIV, and previous experience with HCV treatment was carried out. In addition, participants filled in a questionnaire evaluating 13 statements relating to HCV treatment (right\/wrong) and 15 statements on their personal \u2018pros and cons\u2019 views to start such a treatment assessed with the means of a 6-point Likert scale.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 153 patients (average age 45\u00a0years, male 78%; 106 (69.3%) currently in opioid maintenance treatment, 47 (30.7%) currently admitted to an inpatient detoxification) with an opioid use disorder were investigated. All of them reported having injected drugs at least once in their lives; 97 participants (63.3%) stated that they had been previously diagnosed with HCV infection. Among them, 27\/97 patients (27.8%) reported a previous treatment with interferon; 27\/97 (27.8%) with DAAs; and 32\/97 (33.0%) reported a currently active hepatitis C. Most patients knew about the availability and efficacy of DAAs. However, DAAs\u2019 low rate of side effects, their short treatment duration, and their replacement of interferon, were not correctly evaluated by up to 50.3% of patients. 25\u201340% of 32 patients with currently active hepatitis C prioritized handling of social and other medical issues, e.g., reduction of heroin use, over treatment of hepatitis C.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Although current levels of risky behavior have reportedly been reduced by active PWID over the past few years, educational and motivational interventions to increase hepatitis C treatment uptake should address the gaps in patients\u2019 knowledge.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-024-01068-w","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T08:03:45Z","timestamp":1724832225000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Knowledge of, and attitude towards, the treatment of hepatitis C in people who inject drugs"],"prefix":"10.1186","volume":"21","author":[{"given":"Patrik","family":"Roser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Brunstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Specka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Timm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"K\u00fchnhold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Schifano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udo","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Scherbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"1068_CR1","volume-title":"Global hepatitis report 2024. Action for access in low- and middle-income countries","author":"World Health Organization (WHO)","year":"2024","unstructured":"World Health Organization (WHO). Global hepatitis report 2024. Action for access in low- and middle-income countries. Geneva: WHO; 2024."},{"issue":"12","key":"1068_CR2","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192\u2013207.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"1068_CR3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1186\/s12879-019-4284-9","volume":"19","author":"R Han","year":"2019","unstructured":"Han R, Zhou J, Fran\u00e7ois C, Toumi M. Prevalence of hepatitis C infection among the general population and high-risk groups in the EU\/EEA: a systematic review update. BMC Infect Dis. 2019;19(1):655.","journal-title":"BMC Infect Dis"},{"key":"1068_CR4","first-page":"7","volume":"38","author":"G Steffen","year":"2022","unstructured":"Steffen G, Behnke AS, Dudareva S, Hommes F, Krings A, Kollan C, et al. Virushepatitis C im Jahr 2021. Epid Bull. 2022;38:7\u201325.","journal-title":"Epid Bull"},{"issue":"10049","key":"1068_CR5","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","volume":"388","author":"JD Stanaway","year":"2016","unstructured":"Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388(10049):1081\u20138.","journal-title":"Lancet"},{"issue":"1\u20132","key":"1068_CR6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3109\/10826080902873044","volume":"45","author":"N Scherbaum","year":"2010","unstructured":"Scherbaum N, Specka M, Schifano F, Bombeck J, Marrziniak B. Longitudinal observation of a sample of German drug consumption facility clients. Subst Use Misuse. 2010;45(1\u20132):176\u201389.","journal-title":"Subst Use Misuse"},{"issue":"13","key":"1068_CR7","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gon\u00e7ales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975\u201382.","journal-title":"N Engl J Med"},{"issue":"8","key":"1068_CR8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1155\/2014\/549624","volume":"28","author":"AHL Yau","year":"2014","unstructured":"Yau AHL, Yoshida EM. Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral, interferon-free antiviral reginens: a concise review. Can J Gastroenterol Hepatol. 2014;28(8):445\u201351.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"3","key":"1068_CR9","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","volume":"59","author":"C H\u00e9zode","year":"2013","unstructured":"H\u00e9zode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) \u2013 NCT01514890. J Hepatol. 2013;59(3):434\u201341.","journal-title":"J Hepatol"},{"issue":"8","key":"1068_CR10","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/ndt\/gfg209","volume":"18","author":"A Bruchfeld","year":"2003","unstructured":"Bruchfeld A, Lindahl K, Stahle L, S\u00f6derberg M, Schvarcz R. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant. 2003;18(8):1573\u201380.","journal-title":"Nephrol Dial Transplant"},{"issue":"25","key":"1068_CR11","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1056\/NEJMcp1006613","volume":"364","author":"HR Rosen","year":"2011","unstructured":"Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011;364(25):2429\u201338.","journal-title":"N Engl J Med"},{"issue":"9","key":"1068_CR12","first-page":"CD012143","volume":"9","author":"JC Jakobsen","year":"2017","unstructured":"Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev. 2017;9(9):CD012143.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"1068_CR13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.7326\/M16-2575","volume":"166","author":"O Falade-Nwulia","year":"2017","unstructured":"Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166(9):637\u201348.","journal-title":"Ann Intern Med"},{"issue":"11","key":"1068_CR14","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1093\/cid\/ciz696","volume":"70","author":"C Graf","year":"2020","unstructured":"Graf C, M\u00fccke MM, Dultz G, Peiffer KH, Kubesch A, Ingiliz P, et al. Efficacy of direct-acting antivirals for chronic hepatitis C virus infection in people who inject drugs or receive opioid substitution therapy: a systematic review and meta-analysis. Clin Infect Dis. 2020;70(11):2355\u201365.","journal-title":"Clin Infect Dis"},{"key":"1068_CR15","volume-title":"Global health sector strategy on viral hepatitis 2016\u20132021. Towards ending viral hepatitis","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016\u20132021. Towards ending viral hepatitis. Geneva: World Health Organization; 2016."},{"issue":"6","key":"1068_CR16","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1111\/liv.15550","volume":"43","author":"VH Nguyen","year":"2023","unstructured":"Nguyen VH, Huang DQ, Le MH, Jin M, Lee EY, Henry L, et al. Global treatment rate and barriers to direct-acting antiviral therapy: a systematic review and meta-analysis of 146 studies and 1,760,352 hepatitis C virus patients. Liver Int. 2023;43(6):1195\u2013203.","journal-title":"Liver Int"},{"key":"1068_CR17","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte. Bericht zum Substitutionsregister. 2022. https:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Bundesopiumstelle\/SubstitReg\/Subst_Bericht2022.pdf?__blob=publicationFile. Accessed 11 Jan 2024."},{"issue":"9","key":"1068_CR18","first-page":"137","volume":"116","author":"L Kraus","year":"2019","unstructured":"Kraus L, Seitz N, Schulte B, Cremer-Schaeffer P, Braun B, Gomes de Matos E, et al. Estimation of the number of people with opioid addiction in Germany. Dtsch Arztebl Int. 2019;116(9):137\u201343.","journal-title":"Dtsch Arztebl Int"},{"key":"1068_CR19","doi-asserted-by":"publisher","first-page":"103247","DOI":"10.1016\/j.drugpo.2021.103247","volume":"96","author":"A Amoako","year":"2021","unstructured":"Amoako A, Ortiz-Paredes D, Engler K, Lebouch\u00e9 B, Klein MB. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: a knowledge synthesis. Int J Drug Policy. 2021;96:103247.","journal-title":"Int J Drug Policy"},{"issue":"8","key":"1068_CR20","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/jvh.13685","volume":"29","author":"AT Jones","year":"2022","unstructured":"Jones AT, Briones C, Tran T, Moreno-Walton L, Kissinger PJ. Closing the hepatitis C treatment gap: United States strategies to improve retention in care. J Viral Hepat. 2022;29(8):588\u201395.","journal-title":"J Viral Hepat"},{"issue":"1","key":"1068_CR21","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1186\/s12889-023-16017-8","volume":"23","author":"CR Balsom","year":"2023","unstructured":"Balsom CR, Farrell A, Kelly DV. Barriers and enablers to testing for hepatitis C virus infection in people who inject drugs\u2014a scoping review of the qualitative evidence. BMC Public Health. 2023;23(1):1038.","journal-title":"BMC Public Health"},{"key":"1068_CR22","volume-title":"European addiction severity index EuropASI: manual for training and application","author":"B Gsellhofer","year":"1999","unstructured":"Gsellhofer B, K\u00fcfner H, Vogt M, Weiler D. European addiction severity index EuropASI: manual for training and application. Munich: Institute for Therapy Research; 1999."},{"issue":"1","key":"1068_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12954-019-0338-y","volume":"17","author":"J Enkelmann","year":"2020","unstructured":"Enkelmann J, Gassowski M, Nielsen S, Wenz B, Ro\u00df S, Marcus U, et al. High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011\u20132014: missed opportunities for hepatitis C testing. Harm Reduct J. 2020;17(1):7.","journal-title":"Harm Reduct J"},{"key":"1068_CR24","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1186\/s12889-016-3545-4","volume":"16","author":"B Wenz","year":"2016","unstructured":"Wenz B, Nielsen S, Gassowski M, Santos-H\u00f6vener C, Cai W, Ross RS, et al. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011\u20132014). BMC Public Health. 2016;16:927.","journal-title":"BMC Public Health"},{"issue":"1","key":"1068_CR25","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12879-019-3839-0","volume":"19","author":"RJM Bom","year":"2019","unstructured":"Bom RJM, van der Linden K, Matser A, Poulin N, Schim van der Loeff MF, Bakker BHW, et al. The effects of free condom distribution on HIV and other sexually transmitted infections in men who have sex with men. BMC Infect Dis. 2019;19(1):222.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"1068_CR26","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1360-0443.2009.02888.x","volume":"105","author":"N Palmateer","year":"2010","unstructured":"Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction. 2010;105(5):844\u201359.","journal-title":"Addiction"},{"key":"1068_CR27","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.2147\/RMHP.S244720","volume":"14","author":"V Tran","year":"2021","unstructured":"Tran V, Reid SE, Roxburgh A, Day CA. Assessing drug consumption rooms and longer term (5 year) impacts on community and clients. Risk Manag Healthc Policy. 2021;14:4639\u201347.","journal-title":"Risk Manag Healthc Policy"},{"issue":"Suppl 6","key":"1068_CR28","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1186\/1471-2334-14-S6-S16","volume":"14","author":"JV Lazarus","year":"2014","unstructured":"Lazarus JV, Sperle I, Maticic M, Wiessing L. A systematic review of hepatitis C virus treatment uptake among people who inject drugs in the European region. BMC Infect Dis. 2014;14(Suppl 6):S16.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"1068_CR29","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"European Association for the Study of the Liver","year":"2020","unstructured":"European Association for the Study of the Liver. EASL recommendations on the treatment of hepatitis C: final update of the series. J Hepatol. 2020;73(5):1170\u2013218.","journal-title":"J Hepatol"},{"issue":"7","key":"1068_CR30","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/jvh.12869","volume":"25","author":"M Harris","year":"2018","unstructured":"Harris M, Bonnington O, Harrison G, Hickman M, Irving W. Understanding hepatitis C intervention success\u2014qualitative findings from the HepCATT study. J Viral Hepat. 2018;25(7):762\u201370.","journal-title":"J Viral Hepat"},{"issue":"4","key":"1068_CR31","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/14659891.2019.1704076","volume":"25","author":"B Tofighi","year":"2020","unstructured":"Tofighi B, Lee JD, Sindhu SS, Chemi C, Leonard NR. Engagement in the hepatitis C care continuum among people who use drugs. J Subst Use. 2020;25(4):343\u20139.","journal-title":"J Subst Use"},{"issue":"1","key":"1068_CR32","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13722-021-00260-8","volume":"16","author":"JI Tsui","year":"2021","unstructured":"Tsui JI, Barry MP, Austin EJ, Sweek EW, Tung E, Hansen RN, et al. \u2018Treat my whole person, not just my condition\u2019: qualitative explorations of hepatitis C care delivery preferences among people who inject drugs. Addict Sci Clin Pract. 2021;16(1):52.","journal-title":"Addict Sci Clin Pract"},{"key":"1068_CR33","doi-asserted-by":"publisher","first-page":"103019","DOI":"10.1016\/j.drugpo.2020.103019","volume":"88","author":"KM Ward","year":"2021","unstructured":"Ward KM, McCormick SD, Sulkowski M, Latkin C, Chander G, Falade-Nwulia O. Perceptions of network based recruitment for hepatitis C testing and treatment among persons who inject drugs: a qualitative exploration. Int J Drug Policy. 2021;88:103019.","journal-title":"Int J Drug Policy"},{"key":"1068_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7517-11-1","volume":"11","author":"JA Barocas","year":"2014","unstructured":"Barocas JA, Brennan MB, Hull SJ, Stokes S, Fangman JJ, Westergaard RP. Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study. Harm Reduct J. 2014;11:1.","journal-title":"Harm Reduct J"},{"issue":"9","key":"1068_CR35","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1111\/add.16200","volume":"118","author":"C Bharat","year":"2023","unstructured":"Bharat C, Webb P, Wilkinson Z, McKetin R, Grebely J, Farrell M, et al. Agreement between self-reported illicit drug use and biological samples: a systematic review and meta-analysis. Addiction. 2023;118(9):1624\u201348.","journal-title":"Addiction"},{"key":"1068_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41124-016-0016-6","volume":"1","author":"S Nielsen","year":"2016","unstructured":"Nielsen S, Gassowski M, Wenz B, Bannert N, Bock CT, K\u00fccherer C, et al. Concordance between self-reported and measured HIV and hepatitis C virus infection status among people who inject drugs in Germany. Hepatol Med Policy. 2016;1:8.","journal-title":"Hepatol Med Policy"},{"issue":"2","key":"1068_CR37","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/dar.12895","volume":"38","author":"H Coupland","year":"2019","unstructured":"Coupland H, White B, Bates A, Park JN, Iversen J, Maher L. Engaging people who inject drugs in hepatitis C virus testing and prevention through community-based outreach, in Sydney, Australia. Drug Alcohol Rev. 2019;38(2):177\u201384.","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"1068_CR38","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1093\/cid\/ciaa612","volume":"73","author":"J Grebely","year":"2021","unstructured":"Grebely J, Tran L, Degenhardt L, Dowell-Day A, Santo T, Larney S, et al. Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs: a systematic review and meta-analysis. Clin Infect Dis. 2021;73(1):e107\u201318.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"1068_CR39","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1093\/cid\/cit307","volume":"57","author":"J Reimer","year":"2013","unstructured":"Reimer J, Schmidt CS, Schulte B, Gansefort D, G\u00f6lz J, Gerken G, et al. Psychoeducation improves hepatitis C virus treatment during opioid substitution therapy: a controlled, prospective multicenter trial. Clin Infect Dis. 2013;57(Suppl 2):S97-104.","journal-title":"Clin Infect Dis"},{"key":"1068_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jsat.2019.01.021","volume":"100","author":"O Falade-Nwulia","year":"2019","unstructured":"Falade-Nwulia O, Irvin R, Merkow A, Sulkowski M, Niculescu A, Olsen Y, et al. Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore. J Subst Abuse Treat. 2019;100:45\u201351.","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"1068_CR41","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/MEG.0b013e32832a8c4c","volume":"22","author":"J Grebely","year":"2010","unstructured":"Grebely J, Knight E, Genoway KA, Viljoen M, Khara M, Elliott D, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol. 2010;22(3):270\u20137.","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01068-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01068-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01068-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T08:15:47Z","timestamp":1724832947000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01068-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1068"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01068-w","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]},"assertion":[{"value":"19 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients who agreed to participate to the study provided written informed consent prior to data collection. The study was approved by the Ethics Committee of the Medical Faculty of the University of Duisburg-Essen (Ref. No. 18-8146-BO).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"160"}}